Melatonin suppression by melanopsin-weighted light in patients with bipolar I disorder compared to healthy controls
Journal
Journal of psychiatry & neuroscience : JPN
ISSN: 1488-2434
Titre abrégé: J Psychiatry Neurosci
Pays: Canada
ID NLM: 9107859
Informations de publication
Date de publication:
01 03 2020
01 03 2020
Historique:
entrez:
26
2
2020
pubmed:
26
2
2020
medline:
11
11
2021
Statut:
ppublish
Résumé
Multiple lines of evidence suggest that the onset and course of bipolar disorder is influenced by environmental light conditions. Increased suppression of melatonin by light (supersensitivity) in patients with bipolar disorder has been postulated as an endophenotype by several studies. However, due to methodological shortcomings, the results of these studies remain inconclusive. This study investigated melatonin suppression in euthymic patients with bipolar I disorder using evening blue light specifically targeting the melanopsin system. Melatonin suppression was assessed in euthymic patients with bipolar I disorder and healthy controls by exposure to monochromatic blue light (λmax = 475 nm; photon density = 1.6 × 1013 photons/cm2/s) for 30 minutes at 2300 h, administered via a ganzfeld dome for highly uniform light exposure. Serum melatonin concentrations were determined from serial blood sampling via radioimmunoassay. All participants received mydriatic eye drops and were genotyped for the PER3 VNTR polymorphism to avoid or adjust for potential confounding. As secondary outcomes, serum melatonin concentrations during dark conditions and after monochromatic red light exposure (λmax = 624 nm; photon density = 1.6 × 1013 photons/cm2/s) were also investigated. Changes in subjective alertness were investigated for all 3 lighting conditions. A total of 90 participants (57 controls, 33 bipolar I disorder) completed the study. Melatonin suppression by monochromatic blue light did not differ between groups (F1,80 = 0.56; p = 0.46). Moreover, there were no differences in melatonin suppression by monochromatic red light (F1,82 = 1.80; p = 0.18) or differences in melatonin concentrations during dark conditions (F1,74 = 1.16; p = 0.29). Healthy controls displayed a stronger increase in subjective alertness during exposure to blue light than patients with bipolar I disorder (t85 = 2.28; p = 0.027). Large interindividual differences in melatonin kinetics may have masked a true difference. Despite using a large cohort and highly controlled laboratory conditions, we found no differences in melatonin suppression between euthymic patients with bipolar I disorder and healthy controls. These findings do not support the notion that supersensitivity is a valid endophenotype in bipolar I disorder.
Sections du résumé
Background
Multiple lines of evidence suggest that the onset and course of bipolar disorder is influenced by environmental light conditions. Increased suppression of melatonin by light (supersensitivity) in patients with bipolar disorder has been postulated as an endophenotype by several studies. However, due to methodological shortcomings, the results of these studies remain inconclusive. This study investigated melatonin suppression in euthymic patients with bipolar I disorder using evening blue light specifically targeting the melanopsin system.
Methods
Melatonin suppression was assessed in euthymic patients with bipolar I disorder and healthy controls by exposure to monochromatic blue light (λmax = 475 nm; photon density = 1.6 × 1013 photons/cm2/s) for 30 minutes at 2300 h, administered via a ganzfeld dome for highly uniform light exposure. Serum melatonin concentrations were determined from serial blood sampling via radioimmunoassay. All participants received mydriatic eye drops and were genotyped for the PER3 VNTR polymorphism to avoid or adjust for potential confounding. As secondary outcomes, serum melatonin concentrations during dark conditions and after monochromatic red light exposure (λmax = 624 nm; photon density = 1.6 × 1013 photons/cm2/s) were also investigated. Changes in subjective alertness were investigated for all 3 lighting conditions.
Results
A total of 90 participants (57 controls, 33 bipolar I disorder) completed the study. Melatonin suppression by monochromatic blue light did not differ between groups (F1,80 = 0.56; p = 0.46). Moreover, there were no differences in melatonin suppression by monochromatic red light (F1,82 = 1.80; p = 0.18) or differences in melatonin concentrations during dark conditions (F1,74 = 1.16; p = 0.29). Healthy controls displayed a stronger increase in subjective alertness during exposure to blue light than patients with bipolar I disorder (t85 = 2.28; p = 0.027).
Limitations
Large interindividual differences in melatonin kinetics may have masked a true difference.
Conclusion
Despite using a large cohort and highly controlled laboratory conditions, we found no differences in melatonin suppression between euthymic patients with bipolar I disorder and healthy controls. These findings do not support the notion that supersensitivity is a valid endophenotype in bipolar I disorder.
Identifiants
pubmed: 32096617
doi: 10.1503/jpn.190005
pmc: PMC7828907
doi:
Substances chimiques
Rod Opsins
0
melanopsin
0
Melatonin
JL5DK93RCL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
79-87Informations de copyright
© 2020 Joule Inc. or its licensors
Déclaration de conflit d'intérêts
D. Skene is a co-director of Stockerland Ltd., UK. M. Bauer reports grants from Deutsche Forschungsgemeinscheaft (DFG), and Bundesministerium für Bildung und Forschung (BMBF); personal fees from Allergan, Aristo, Janssen, Lundbeck, Neuraxpharm, Sandoz, Servier and Sumitomo Dainippon; and nonfinancial support from Lilly, Neuraxpharm and Servier, all outside the submitted work. B. Soltmann is supported by a grant from the German Ministry of Research and Education (grant no. 13N13399). No other competing interests declared.
Références
J Clin Endocrinol Metab. 2012 Mar;97(3):E433-7
pubmed: 22188742
Bipolar Disord. 2005 Feb;7(1):98-101
pubmed: 15654938
Annu Rev Neurosci. 2017 Jul 25;40:539-556
pubmed: 28525301
Int J Neuropsychopharmacol. 2005 Jun;8(2):255-9
pubmed: 15850501
Eur Neuropsychopharmacol. 2007 Sep;17(9):587-94
pubmed: 17512705
Int J Neurosci. 1990 May;52(1-2):29-37
pubmed: 2265922
Eye (Lond). 2016 Feb;30(2):247-54
pubmed: 26768919
Biol Psychiatry. 2001 Apr 1;49(7):624-36
pubmed: 11297720
Pharmacol Res. 2012 Apr;65(4):437-44
pubmed: 22311380
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Neurosci Lett. 2008 Nov 14;445(2):184-7
pubmed: 18789374
Psychol Med. 1996 May;26(3):477-86
pubmed: 8733206
J Psychiatr Res. 2015 May;64:1-8
pubmed: 25862378
Bipolar Disord. 2012 Sep;14(6):654-63
pubmed: 22612720
Am J Physiol Regul Integr Comp Physiol. 2006 May;290(5):R1421-8
pubmed: 16439671
Acta Neuropsychiatr. 2009 Oct;21(5):246-55
pubmed: 26952772
Psychiatry Res. 1991 Jul;38(1):13-9
pubmed: 1658841
Psychiatry Res. 1990 Aug;33(2):129-34
pubmed: 2243889
J Affect Disord. 2014 Oct;168:210-23
pubmed: 25063960
Science. 2002 Feb 8;295(5557):1065-70
pubmed: 11834834
Br J Psychiatry. 1978 Nov;133:429-35
pubmed: 728692
Nat Neurosci. 2001 Jun;4(6):621-6
pubmed: 11369943
J Affect Disord. 2014;167:104-11
pubmed: 24953482
PLoS One. 2013;8(1):e53583
pubmed: 23301090
Am J Psychiatry. 1985 Jun;142(6):725-7
pubmed: 4003592
Eur J Neurosci. 2014 Jul;40(1):2206-15
pubmed: 24898566
J Neurosci. 2001 Aug 15;21(16):6405-12
pubmed: 11487664
J Physiol. 2001 Aug 15;535(Pt 1):261-7
pubmed: 11507175
Bipolar Disord. 2016 May;18(3):221-32
pubmed: 27226262
J Affect Disord. 2001 Feb;62(3):221-3
pubmed: 11223110
Neuropsychopharmacology. 1999 Sep;21(3):408-13
pubmed: 10457538
Lancet. 1981 Feb 14;1(8216):383-4
pubmed: 6110011
Int J Chronobiol. 1976;4(2):97-110
pubmed: 1027738
Arch Gen Psychiatry. 2000 Jun;57(6):572-9
pubmed: 10839335
Optometry. 2006 Jul;77(7):350-3
pubmed: 16814239
Neuropsychopharmacology. 2005 Jul;30(7):1400-4
pubmed: 15841104
Hum Mol Genet. 2012 Sep 15;21(18):4030-7
pubmed: 22694957
Psychoneuroendocrinology. 1989;14(3):187-93
pubmed: 2756073
Front Syst Neurosci. 2014 Jul 08;8:126
pubmed: 25071478
J Clin Endocrinol Metab. 2003 Sep;88(9):4502-5
pubmed: 12970330